Material Transfer Agreement (MTA) · Material Transfer Agreement (MTA) ... The Uniform Biological...

Material Transfer Agreement (MTA)

http://web.research.colostate.edu/(X(1)S(tmu43k55tvrsiz55ogbggnzx))/OSP/mta.aspx?AspxAutoDetectCookieSupport=1[2012/07/13 16:30:55]

Office Links

Finding Information:

Internal Resources:

Home

Contact Information

Organization Chart

Staff Directory

Policies and Manuals

Export Control


Funding Opportunities

Proposal Preparation Resources

Accounting Resources

Research Data Center

Internal Research Contacts

External Research Contacts

Research Site Map

CSU A-Z

Search CSU

Directories

Research Portal (restricted)

Check Email (restricted)


Scientific materials being transferred between CSU and another organization must be formally coveredwith a Material Transfer Agreement (MTA). The purpose of the MTA is to protect the intellectual andother property rights of the provider while permitting research with the material to proceed. Theseagreements describe the terms and purpose of the exchange, including intellectual property rights,liability issues, publication, confidentiality, royalties or other financial terms, and the specifics of thematerials and their transfer.

General Information (PDF)Instructions UBMTA (PDF)Instructions Non UBMTA (PDF)

Forms

The Uniform Biological Material Transfer Agreement (PDF)UBMTA Implementing Letter (Fillable PDF)CSU Biological MTA Long Form (Fillable PDF)CSU Biological MTA Short Form (Fillable PDF)Material Transfer Agreement (Fillable PDF)

Other Resources

UBMTA Members

Material Transfer in Academia an informative booklet from COGR about entering into MaterialTransfer Agreements. (PDF)

For additional information, please contact:

Betty [email protected](970) 491-1554

Contact CSU | Disclaimer | Equal Opportunity | Privacy Statement

Colorado State University, Fort Collins, CO 80523 USA 2007 Colorado State University

This page has been accessed 5312 times.

http://web.research.colostate.edu/OSP/default.aspxhttp://web.research.colostate.edu/OSP/default.aspxhttp://web.research.colostate.edu/OSP/contact.aspxhttp://web.research.colostate.edu/OSP/contact.aspxhttp://web.research.colostate.edu/OSP/staff_chart.aspxhttp://web.research.colostate.edu/OSP/staff_chart.aspxhttp://web.research.colostate.edu/OSP/policies.aspxhttp://web.research.colostate.edu/OSP/policies.aspxhttp://web.research.colostate.edu/OSP/export.aspxhttp://web.research.colostate.edu/OSP/export.aspxhttp://web.research.colostate.edu/OSP/mta.aspxhttp://web.research.colostate.edu/OSP/mta.aspxhttp://web.research.colostate.edu/OSP/funding.aspxhttp://web.research.colostate.edu/OSP/funding.aspxhttp://web.research.colostate.edu/OSP/proposal.aspxhttp://web.research.colostate.edu/OSP/proposal.aspxhttp://web.research.colostate.edu/OSP/accounting.aspxhttp://web.research.colostate.edu/OSP/accounting.aspxhttp://web.research.colostate.edu/datacenter/http://web.research.colostate.edu/datacenter/http://web.research.colostate.edu/OSP/internal.aspxhttp://web.research.colostate.edu/OSP/internal.aspxhttp://web.research.colostate.edu/OSP/external.aspxhttp://web.research.colostate.edu/OSP/external.aspxhttp://web.research.colostate.edu/vpr/sitemap.aspxhttp://web.research.colostate.edu/vpr/sitemap.aspxhttp://search.colostate.edu/search-atoz.aspxhttp://search.colostate.edu/search-atoz.aspxhttp://search.colostate.edu/search-csu.aspxhttp://search.colostate.edu/search-csu.aspxhttp://search.colostate.edu/search-directory.aspxhttp://search.colostate.edu/search-directory.aspxhttp://padroni.is.colostate.edu:7778/portal/page/portal/CSUCAP/Researchhttp://padroni.is.colostate.edu:7778/portal/page/portal/CSUCAP/Researchhttp://mail.colostate.edu/http://mail.colostate.edu/mailto:[email protected]://search.colostate.edu/index.asp?url=contact_informationhttp://welcome.colostate.edu/info-disclaimer.aspxhttp://welcome.colostate.edu/info-equalop.aspxhttp://welcome.colostate.edu/info-privacy.aspxhttp://web.research.colostate.edu/OSPhttp://www.colostate.edu/http://vpr.colostate.edu/

Revised 12/14/07 sf

Material Transfer Agreements

General Information

Scientific materials being transferred between CSU and another organization must be formally

covered with a Material Transfer Agreement (MTA). The purpose of the MTA is to protect the

intellectual and other property rights of the provider while permitting research with the material

to proceed. These agreements describe the terms and purpose of the exchange, including

intellectual property rights, liability issues, publication, confidentiality, royalties or other

financial terms, and the specifics of the materials and their transfer. The MTAs may be between

CSU and other universities, governmental agencies such as NIH, or, more frequently,

commercial entities. It is important to recognize that these agreements are between institutions,

not individuals. Sponsored Programs is responsible for review and approval of all MTAs for

materials coming into CSU and for non-UBMTA outgoing materials.

IMPORTANT

Private companies generally regard any materials they provide to the academic community as

highly proprietary and provide the materials as a favor only if the recipient organization agrees to

certain terms. Usually the terms involve some first right of the provider to a license to any

discoveries made by the Principal Investigator (PI) as a result of using the companys materials.

Some of the company-proposed terms may be in conflict with CSUs policies and/or federal

guidelines. The staff in Sponsored Programs will work with the provider company to arrive at

terms which are consistent with CSU policy and, for NIH Guidelines if the PI is a NIH grant

recipient. Deviations from CSU policy will require the approval of the VPRs Office.

If the material is the subject of a patent application which has been filed by CSU, OR the

material incorporates any substance which was received from a third party under an MTA, you

should consult your Senior Research Administrator for assistance.

NIH Guidelines:

The National Institutes of Health (NIH) published its policy statement in the December 23, 1999

Federal Register entitled "Principles and Guidelines for Recipients of NIH Research Grants and

Contracts on Obtaining and Disseminating Biomedical Research Resources". These guidelines

are intended to help federal grant recipients determine reasonable terms and conditions for

making NIH funded research resources available to others and under what terms and conditions

NIH funded scientist should receive materials from others. The Guidelines can be found at

http://ott.od.nih.gov/policy/rt_guide.html.

For all MTA transactions please complete the MTA Information Sheet; this form can be found at

(http://web.research.colostate.edu/osp/mta/pdf/newmta.pdf. The format of the agreement to be

used for material transfers will depend upon whether or not the other party is a member to the

Universal Biomedical Material Transfer Agreement (UBMTA). If the other party is a participant

in the UBMTA, the following procedures apply. If they are not a member to the UBMTA,

please refer to the section labeled NON-UBMTA Members.

Updated 12/14/2007 sf

Material Transfer Agreements

Instructions - UBMTA For all MTA transactions please complete the MTA Information Sheet; this form can be found at (http://web.research.colostate.edu/osp/mta/pdf/newmta.pdf. Background: On March 8, 1995, the National Institutes of Health (NIH) (on behalf of the Public Health Service and the Centers for Disease Control) published the final version of the Uniform Biological Material Transfer Agreement (UBMTA) and a Simple Letter Agreement for the Transfer of Non-Proprietary Biological Material. For institutions, such as CSU, which have signed the UBMTA Master Agreement, materials can be transferred under the terms of the UBMTA upon execution of an Implementing Letter for the particular transfer. The UBMTA is appropriate for most transfers of materials between CSU and other academic institutions. To determine if the academic institution you are working with is a signatory to the UBMTA, click on this link http://www.autm.net/Technology_Transfer_Resources/8199.htm. Process: Out-Going Materials The Scientist from the Recipient organization should complete three copies of the Implementing Letter and obtain signatures as necessary from his/her organization. Upon receipt of the signed copies, CSUs PI should sign the Implementing Letters where indicated and return one fully executed copy along with the materials to the Recipient. The second copy of the Letter should be retained by the CSU PI with the third copy being sent to Sponsored Programs. In-Coming Materials CSUs PI should obtain and sign three copies of the Implementing Letter as the Recipient. The copies along with the MTA Information Sheet should be forwarded to the Senior Research Administrator assigned to their College for review and approval. The Letters will be returned to the PI to be mailed to the Provider with a request to return two fully signed copies. One copy should be retained by the CSU PI and the second forwarded to Sponsored Programs. If the incoming material is subject to approval of the Research Integrity and Compliance Review Office, this approval must be obtained prior to executing the MTA. If you have questions about MTAs, contact the SRA responsible for your college.

Updated 12/17/07 sf

Material Transfer Agreements Non UBMTA Members

Instructions Non UBMTA

For all MTA transactions please complete the MTA Information Sheet; this form can be found at

(http://web.research.colostate.edu/osp/mta/pdf/newmta.pdf.

Out-Going Materials - For materials being transferred from CSU, a model MTA form can be

found at http://web.research.colostate.edu/osp/mta/pdf/csumta.pdf. Please provide the Recipient

with this link. The Recipient should complete and sign three separate copies of this agreement

and forward them to the PI. When the copies are received, the PI should sign as the Provider

Scientist and forward the copies to Sponsored Programs (SP). SP will review and approve the

documents and return two copies to the PI; one for your files and one to be sent to the Recipient

with the materials.

In-Coming Materials - For materials being transferred to CSU, the other party typically uses its

own MTA form, yet your handling of the MTA in the following way will expedite the process.

Review the MTA carefully for terms that could cause your laboratory difficulty. These might

include confidentiality issues, publication issues, quantities or timing of materials transferred.

Watch out for terms that would be in conflict with other terms (research contract, other MTAs, or

government sponsor requirements) and discuss with your Senior Research Administrator (SRA)

(http://web.research.colostate.edu/OSP/staff_detail.aspx).

If the incoming material is subject to approval of the Regulatory Compliance Office, this approval must be obtained prior to the execution of the MTA.

Sign and date it as the technical (not institutional) representative this may require adding a signature block.

Send three originals of the agreement and one copy of the MTA Information Sheet to the SRA responsible for your college, 408 USC, 2002 Campus Delivery.

At Sponsored Programs the MTA will be checked for intellectual property rights, liability issues, and other legal matters.

If the terms are inconsistent with University policy, the SRA will attempt to negotiate acceptable language with the other party, keeping you informed.

If the terms are acceptable, the SRA will obtain an authorized signature, and the MTA will be returned to you for delivery to the other party.

Be sure to retain a copy of the MTA, since you, as the Recipient, will be obligated to abide by its terms. If any of the terms are unclear, contact the SRA for your college.

Please allow plenty of time for an MTA to be processed since it can take several days to negotiate mutually acceptable terms.

If you have questions about MTAs, contact the SRA responsible for your college.

Updated 12/17/07 sf

The Uniform Biological Material Transfer Agreement

March 8, 1995

I. Definitions:

1. PROVIDER: Organization providing the ORIGINAL MATERIAL. The name and

address of this party will be specified in an implementing letter.

2. PROVIDER SCIENTIST: The name and address of this party will be specified in an

implementing letter.

3. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The name and

address of this party will be specified in an implementing letter.

4. RECIPIENT SCIENTIST: The name and address of this party will be specified in an

implementing letter.

5. ORIGINAL MATERIAL: The description of the material being transferred will be

specified in an implementing letter.

6. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED

DERIVATIVES. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other

substances created by the RECIPIENT through the use of the MATERIAL which are not

MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES.

7. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus,

cell from cell, or organism from organism.

8. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which

constitute an unmodified functional subunit or product expressed by the ORIGINAL

MATERIAL. Some examples include: subclones of unmodified cell lines, purified or

fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied

by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.

9. MODIFICATIONS: Substances created by the RECIPIENT which

contain/incorporate the MATERIAL.

10. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the

MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES

shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including

RECIPIENT, to perform contract research, to screen compound libraries, to produce or

manufacture products for general sale, or to conduct research activities that result in any sale,

lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization.

However, industrially sponsored academic research shall not be considered a use of the

Updated 12/17/07 sf

MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the

above conditions of this definition are met.

11. NONPROFIT ORGANIZATION(S): A university or other institution of higher

education or an organization of the type described in section 501(c)(3) of the Internal Revenue

Code of 1954 (26 U.S.C. 501(c)) and exempt from taxation under section 501(a) of the Internal

Revenue Code (26 U.S.C. 501(a)) or any nonprofit scientific or educational organization

qualified under a state nonprofit organization statute. As used herein, the term also includes

government agencies.

II. Terms and Conditions of this Agreement:

1. The PROVIDER retains ownership of the MATERIAL, including any MATERIAL

contained or incorporated in MODIFICATIONS.

2. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, the

PROVIDER retains ownership rights to the MATERIAL included therein), and (b) those

substances created through the use of the MATERIAL or MODIFICATIONS, but which are not

PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not contain the

ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either 2 (a) or 2 (b)

results from the collaborative efforts of the PROVIDER and the RECIPIENT, joint ownership

may be negotiated.

3. The RECIPIENT and the RECIPIENT SCIENTIST agree that the MATERIAL:

(a) is to be used solely for teaching and academic research purposes;

(b) will not be used in human subjects, in clinical trials, or for diagnostic

purposes involving human subjects without the written consent of the

PROVIDER;

(c) is to be used only at the RECIPIENT organization and only in the

RECIPIENT SCIENTIST's laboratory under the direction of the RECIPIENT

SCIENTIST or others working under his/her direct supervision; and

(d) will not be transferred to anyone else within the RECIPIENT organization

without the prior written consent of the PROVIDER.

4. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER

any request for the MATERIAL from anyone other than those persons working under the [[Page

12774]] RECIPIENT SCIENTIST's direct supervision. To the extent supplies are available, the

PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL available, under a

separate implementing letter to this Agreement or other agreement having terms consistent with

the terms of this Agreement, to other scientists (at least those at NONPROFIT

ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTIST's research; provided

Updated 12/17/07 sf

that such other scientists reimburse the PROVIDER for any costs relating to the preparation and

distribution of the MATERIAL.

5.

(a) The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the right,

without restriction, to distribute substances created by the RECIPIENT through

the use of the ORIGINAL MATERIAL only if those substances are not

PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.

(b) Under a separate implementing letter to this Agreement (or an agreement at

least as protective of the PROVIDER's rights), the RECIPIENT may distribute

MODIFICATIONS to NONPROFIT ORGANIZATION(S) for research and

teaching purposes only.

(c) Without written consent from the PROVIDER, the RECIPIENT and/or the

RECIPIENT SCIENTIST may NOT provide MODIFICATIONS for

COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such

COMMERCIAL PURPOSES may require a commercial license from the

PROVIDER and the PROVIDER has no obligation to grant a commercial license

to its ownership interest in the MATERIAL incorporated in the

MODIFICATIONS. Nothing in this paragraph, however, shall prevent the

RECIPIENT from granting commercial licenses under the RECIPIENT's

intellectual property rights claiming such MODIFICATIONS, or methods of their

manufacture or their use.

6. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a

patent application. Except as provided in this Agreement, no express or implied licenses or other

rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or

other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made

by the PROVIDER. In particular, no express or implied licenses or other rights are provided to

use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for

COMMERCIAL PURPOSES.

7. If the RECIPIENT desires to use or license the MATERIAL or MODIFICATIONS

for COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate

in good faith with the PROVIDER to establish the terms of a commercial license. It is

understood by the RECIPIENT that the PROVIDER shall have no obligation to grant such a

license to the RECIPIENT, and may grant exclusive or non-exclusive commercial licenses to

others, or sell or assign all or part of the rights in the MATERIAL to any third party(ies), subject

to any pre-existing rights held by others and obligations to the Federal Government.

8. The RECIPIENT is free to file patent application(s) claiming inventions made by the

RECIPIENT through the use of the MATERIAL but agrees to notify the PROVIDER upon filing

a patent application claiming MODIFICATIONS or method(s) of manufacture or use(s) of the

MATERIAL.

Updated 12/17/07 sf

9. Any MATERIAL delivered pursuant to this Agreement is understood to be

experimental in nature and may have hazardous properties. The PROVIDER MAKES NO

REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER

EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF

MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE

OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK,

OR OTHER PROPRIETARY RIGHTS.

10. Except to the extent prohibited by law, the RECIPIENT assumes all liability for

damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER

will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or

made against the RECIPIENT by any other party, due to or arising from the use of the

MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the

gross negligence or willful misconduct of the PROVIDER.

11. This agreement shall not be interpreted to prevent or delay publication of research

findings resulting from the use of the MATERIAL or the MODIFICATIONS. The RECIPIENT

SCIENTIST agrees to provide appropriate acknowledgement of the source of the MATERIAL in

all publications.

12. The RECIPIENT agrees to use the MATERIAL in compliance with all applicaple

statutes and regulations, including Public Health Service and National Institutes of Health

regulations and guidelines such as, for example, those relating to research involving the use of

animals or recombinant DNA.

13. This Agreement will terminate on the earliest of the following dates: (a) when the

MATERIAL becomes generally available from third parties, for example, though reagent

catalogs or public depositories or (b) on completion of the RECIPIENT's current research with

the MATERIAL, or (c) on thirty (30) days written notice by either party to the other, or (d) on

the date specified in an implementing letter, provided that:

(i) if termination should occur under 13(a), the RECIPIENT shall be bound to the

PROVIDER by the least restrictive terms applicable to the MATERIAL obtained from

the then-available resources; and

(ii) if termination should occur under 13(b) or (d) above, the RECIPIENT will

discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return

or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either

destroy the MODIFICATIONS or remain bound by the terms of this agreement as they

apply to MODIFICATIONS;

and

(iii) in the event the PROVIDER terminates this Agreement under 13(c) other

than for breach of this Agreement or for cause such as an imminent health risk or patent

Updated 12/17/07 sf

infringement, the PROVIDER will defer the effective date of termination for a period of

up to one year, upon request from the RECIPIENT, to permit completion of research in

progress. Upon the effective date of termination, or if requested, the deferred effective

date of termination, RECIPIENT will discontinue its use of the MATERIAL and will,

upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The

RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain

bound by the terms of this agreement as they apply to MODIFICATIONS.

14. Paragraphs 6, 9, and 10 shall survive termination.

15. The MATERIAL is provided at no cost, or with an optional transmittal fee solely to

reimburse the PROVIDER for its preparation and distribution costs. If a fee is requested by the

PROVIDER, the amount will be indicated in an implementing letter.

http://web.research.colostate.edu/osp/mta/pdf/UBMTALetter.pdf[2012/07/13 16:32:11]

Adobe XML http://web.research.colostate.edu/osp/mta/pdf/UBMTALetter.pdf Adobe XML

Updated 2/20/09 sf

UBMTA Implementing Letter The purpose of this letter is to provide a record of the biological material transfer, to memorialize the agreement between the PROVIDER SCIENTIST (identified below) and the RECIPIENT SCIENTIST (identified below) to abide by all terms and conditions of the Uniform Biological Material Transfer Agreement (UBMTA) March 8, 1995, and to certify that the RECIPIENT (identified below) organization has accepted and signed an unmodified copy of the UBMTA. The RECIPIENT organization's Authorized Official also will sign this letter if the RECIPIENT SCIENTIST is not authorized to certify on behalf of the RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized Official of RECIPIENT, if necessary) should sign both copies of this letter and return one signed copy to the PROVIDER. The PROVIDER SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon receipt of the signed copy from the RECIPIENT organization. Please fill in all of the blank lines below: 1. PROVIDER: Organization providing the ORIGINAL MATERIAL:

Organization:

Address:

2. RECIPIENT: Organization receiving the ORIGINAL MATERIAL:

Organization:

Address: 3. ORIGINAL MATERIAL (Enter description):

4. Termination date for this letter (optional): 5. Transmittal Fee to reimburse the PROVIDER for preparation and distribution costs

(optional). Amount:

Updated 2/20/09 sf

This Implementing Letter is effective when signed by all parties. The parties executing this Implementing Letter certify that their respective organizations have accepted and signed an unmodified copy of the UBMTA, and further agree to be bound by its terms, for the transfer specified above. PROVIDER SCIENTIST Name: Title: Address:

Signature: Date: RECIPIENT SCIENTIST Name: Title: Address:

Signature: Date: RECIPIENT ORGANIZATION CERTIFICATION Certification: I hereby certify that the RECIPIENT organization has accepted and signed an unmodified copy of the UBMTA (May be the RECIPIENT SCIENTIST if authorized by the RECIPIENT organization): Authorized Official: Title: Address:

Signature: Date:

TextField1:

UBMTALetter.pdf


Biological Material Transfer Agreement I. Definitions

A. PROVIDER: Organization providing the ORIGINAL MATERIAL. The name and address of this party will be specified on the MTA Implementing Form.

B. PROVIDER SCIENTIST: The name and address of this party will be specified on the MTA Implementing

Form.

C. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The name and address of this party will be specified on the MTA Implementing Form.

D. RECIPIENT SCIENTIST: The name and address of this party will be specified on the MTA Implementing

Form.

E. ORIGINAL MATERIAL: The description of the material being transferred will be specified on the MTA Implementing Form.

F. MATERIAL: ORIGINAL MATERIAL, PROGENY, and UNMODIFIED DERIVATIVES. The

MATERIAL shall not include (a) MODIFICATIONS, or (b) other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES.

G. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or

organism from organism.

H. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. Some examples include: subclones of unmodified cell lines, purified or fractionated subsets of the ORIGINAL MATERIAL, proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.

I. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL.

J. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or

MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrial sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met.

K. NON-PROFIT ORGANIZATION(S): A university or other institution of higher education or an organization of the type described in section 501(c)(3) of the Internal Revenue Code of 1954 (26 USC 501(c)) and exempt from taxation under section 501(a) of the Internal Revenue Code (26 USC 501(a)) or any non-profit scientific or educational organization, qualified under a state non-profit organization statute. As used herein, the term also includes government agencies.


II. Terms and Conditions of this Agreement

A. The PROVIDER retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICATIONS.

B. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, the PROVIDER retains

ownership rights to the MATERIAL included therein), and (b) those Substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS (i.e., do not contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either 2(a) or 2(b) results from the collaborative efforts of the PROVIDER and the RECIPIENT, joint ownership may be negotiated.

C. The RECIPIENT and the RECIPIENT SCIENTIST agree that the MATERIAL:

1. is to be used solely for teaching and academic research purposes; 2. will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human

subjects without the written consent of the PROVIDER; 3. is to be used only at the RECIPIENT organization and only in the RECIPIENT SCIENTISTs

laboratory under the direction of the RECIPIENT SCIENTIST or others working under his/her direct supervision; and

4. will not be transferred to anyone else within the RECIPIENT organization without the prior written consent of the PROVIDER.

D. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER any request for the

MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTISTs direct supervision. To the extent supplies are available, the PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL available, under a separate implementing form, to this Agreement or other agreement having terms consistent with the terms of this Agreement, to other scientists (at least those at NONPROFIT ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTISTs research; provided that such other scientists reimburse the PROVIDER for any costs relating to the preparation and distribution of the MATERIAL.

E. Distribution

1. The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the right, without restriction, to

distribute substances created by the RECIPIENT through the use of the ORIGINAL MATERIAL only if those substances are not PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.

2. Under a separate implementing form to this Agreement (or an agreement at least as protective of the PROVIDERs rights), the RECIPIENT may distribute MODIFICATIONS to NONPROFIT ORGANIZATION(S) for research and teaching purposes only.

3. Without written consent from the PROVIDER, the RECIPIENT and/or the RECIPIENT SCIENTIST may not provide MODIFICATIONS for COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such COMMERCIAL PURPOSES may require a commercial license from the PROVIDER and the PROVIDER has no obligation to grant a commercial license to its ownership interest in the MATERIAL, incorporated in the MODIFICATIONS. Nothing in this paragraph, however, shall prevent the RECIPIENT from granting commercial licenses under the RECIPIENTs intellectual property rights claiming such MODIFICATIONS, or methods of their manufacture or their use.

F. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a patent application.

Except as provided in this Agreement, no express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made by the PROVIDER. In particular, no express or implied licenses or other rights are provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES.


G. If the RECIPIENT desires to use or license the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate in good faith with the PROVIDER to establish the terms of a commercial license. It is understood by the RECIPIENT that the PROVIDER shall have no obligation to grant such a license to the RECIPIENT, and may grant exclusive or non-exclusive commercial licenses to others, or sell or assign all or part of the rights in the MATERIAL to any third party(ies), subject to any pre-existing rights held by others and obligations to the Federal Government.

H. The RECIPIENT is free to file patent application(s) claiming inventions made by the RECIPIENT through

the use of the MATERIAL, but agrees to notify the PROVIDER upon filing a patent application claiming MODIFICATIONS or method(s) of manufacture or use(s) of the MATERIAL.

I. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may

have hazardous properties. The PROVIDER makes no representations and extends no warranties of any kind, either expressed or implied. There are no express or implied warranties of merchantability or fitness for a particular purpose, or that the use of the MATERIAL will not infringe any patent, copyright, trademark, or other proprietary rights.

J. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise

from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER.

K. This Agreement shall not be interpreted to prevent or delay publication of research findings resulting from

the use of the MATERIAL or the MODIFICATIONS. The RECIPIENT SCIENTIST agrees to provide appropriate acknowledgment of the source of the MATERIAL in all publications.

L. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and regulations,

including Public Health Service and National Institutes of Health regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA.

M. This Agreement will terminate on the earliest of the following dates: (a) when the MATERIAL becomes

generally available from third parties, for example, through reagent catalogs or public depositories, or (b) on completion of the RECIPIENTs current research with the MATERIAL, or (c) on thirty (30) days written notice by either party to the other, or (d) on the date specified in an implementing form, provided that: 1. if termination should occur under M(a) above, the RECIPIENT shall be bound to the PROVIDER by

the least restrictive terms applicable to the MATERIAL obtained from the then-available sources; and 2. if termination should occur under M(b) or (d) above, the RECIPIENT will discontinue its use of the

MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS; and

3. in the event the PROVIDER terminates this Agreement under M(c) above other than for breach of this Agreement or for cause such as an imminent health risk or patent infringement, the PROVIDER will defer the effective date of termination for a period of up to one year, upon request from the RECIPIENT, to permit completion of research in progress. Upon the effective date of termination, or if requested, the deferred effective date of termination, RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS.

N. Paragraphs F, I, and J of these terms and conditions shall survive termination.


O. The MATERIAL is provided at no cost, or with an optional transmittal fee solely to reimburse the PROVIDER for its preparation and distribution costs. If a fee is requested by the PROVIDER, the amount will be indicated in an implementing form.

#### End of Agreement Terms and Conditions####


Biological Material Agreement Implementing Form The purpose of this form is to provide a record of the biological material transfer, to memorialize the agreement between the PROVIDER SCIENTIST (identified below), and the RECIPIENT SCIENTIST (identified below) to abide by all terms and conditions of the accompanying Biological Material Transfer Agreement (BMTA), and to certify that the RECIPIENT (identified below) organization has accepted and signed an unmodified copy of the BMTA. The RECIPIENT organizations Authorized Official also will sign this form if the RECIPIENT SCIENTIST is not authorized to certify on behalf of the RECIPIENT organization. The RECIPIENT SCIENTIST (and the Authorized Official of RECIPIENT, if necessary), should sign two copies of this form and return one signed copy to the PROVIDER (scanned signatures are acceptable in lieu of two originals). The PROVIDER SCIENTIST will forward the material to the RECIPIENT SCIENTIST upon receipt of the signed copy from the RECIPIENT organization. This Implementing Form is effective when signed by all parties. The parties executing this Form certify that their respective organizations have accepted and signed the copy of the BMTA, initialing where modifications have been negotiated, and further agree to be bound by the terms of the BMTA, for the transfer specified above. Please fill in all of the blank lines below. 1. ORIGINAL MATERIAL: (describe) 2. Optional Termination Date: 3. Amount of Optional Transmittal Fee: (indicate currency) 4. PROVIDER (Organization providing the ORIGINAL MATERIAL):

a. Name of Organization:

b. Street Address:

c. City/State/Zip+4:

d. Signature: Date:

5. PROVIDER SCIENTIST:

a. Name and Title:

b. Street Address:


d. Signature: Date:

6. RECIPIENT SCIENTIST:

a. Name and Title:

b. Street Address:


d. Signature: Date:

7. RECIPIENT ORGANIZATION CERTIFICATION (Organization receiving the ORIGINAL MATERIAL):

I hereby certify that the RECIPIENT ORGANIZATION has accepted and signed (initialing modifications) a copy of the BMTA.

a. Name of Organization:

b. Name and Title:

c. Street Address:

d. City/State/Zip+4:

e. Signature: Date:

http://web.research.colostate.edu/osp/mta/pdf/shortmta.pdf[2012/07/13 16:33:01]

Adobe XML http://web.research.colostate.edu/osp/mta/pdf/shortmta.pdf AdobeXML


Biological Material Transfer Agreement Colorado State University (CSU)

Recipient Scientist: Recipient Organization: Recipient Address: CSU's Provider Scientist: Provider's CSU Address: Regarding Biological Material identified as: Biological Material to be used for: In response to RECIPIENT'S request for the above-identified Biological Material from Colorado State University (CSU), RECIPIENT ORGANIZATION agrees to the following terms in consideration of receipt of the Biological Material: 1. The above Biological Material is the property of CSU and is made available as a service to the Research community.

Biological Material shall mean the above-referenced Biological Material plus progeny, unmodified derivatives, and any accompanying know-how or data.

2. The Biological Material will not be further distributed to others not affiliated with the RECIPIENT SCIENTIST'S laboratory without the written permission of CSU. CSU reserves the right to make the Biological Material available to others, both profit and non-profit.

3. It is understood that no right to any license of the Biological Material is given or implied by this Agreement. CSU's name will be used for no endorsements.

4. The Biological Material will be used for research purposes only. 5. If RECIPIENT SCIENTIST or RECIPIENT ORGANIZATION wishes to patent or commercialize the Biological

Material or modifications, they will contact CSU prior to such use to negotiate CSU's ownership interests. Ownership will be negotiated in good faith by the parties hereto depending upon a) their relative contribution to the creation of said modifications and derivatives, and b) any applicable laws and regulations relating to inventorship.

6. The Biological Material is experimental in nature and IT IS PROVIDED WITHOUT ANY WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

7. The RECIPIENT SCIENTIST agrees to use the Biological Material in compliance with all applicable Federal, State, and local statutes and regulations. The Biological Material will not be used for in vivo testing in human subjects.

The RECIPIENT SCIENTIST and the authorized representative from the RECIPIENT ORGANIZATION will sign two copies to indicate acceptance of the above terms. Two original signed documents should be returned to CSU's PROVIDER SCIENTIST for signature and routed to Sponsored Programs, 408 USC, Colorado State University, Ft. Collins, CO 80523-2002 for PROVIDER ORGANIZATION signature (scanned signatures are acceptable in lieu of two originals). Direct any questions to 970-491-6355. CSU's PROVIDER SCIENTIST: Signature: Date PROVIDER ORGANIZATIONS AUTHORIZED OFFICIAL: Signature: Date RECIPIENT SCIENTIST: Signature: Date RECIPIENT ORGANIZATION REPRESENTATIVE: NAME/TITLE: Signature: Date

CSU's PROVIDER SCIENTIST:

AUTHORIZED OFFICIAL:

RECIPIENT SCIENTIST:

NAME/TITLE:

TextField1:

shortmta.pdf

Colorado State University Material Transfer Agreement (MTA) Information Sheet

1. Review the MTA. You need to be comfortable with the terms, and know them well enough to abide by them. Sign the MTA only if you find it acceptable. Flag questionable terms to the MTA Administrators attention.

2. Complete this info sheet. 3. Send the MTA (all copies), AND this sheet to Sponsored Programs, 2002 Campus Delivery. You may send this info

sheet by email to the Sponsored Programs Senior Research Administrator (SRA) assigned to your college (http://web.research.colostate.edu/OSP/staff_detail.aspx) or by fax (491-6147).

4. Call the SRA responsible for your college if you have questions.

1. CSU person requesting or providing the material (MTAs must be signed by a CSU non-temporary, salaried state classified employee, administrative professional or faculty member). Please complete ALL fields:

Name: Department:

Contact Info (email, phone & fax numbers):

Best way to contact you:

2. Organization providing the materials to CSU:

3. OR the organization receiving the materials from CSU:

4. Contact information at the outside organization: Name:

Contact Info (email, phone & fax numbers):

5. What materials are being transferred? Please give a brief explanation, in laymens terms, of what these materials are (e.g., a proprietary drug, a plasmid, a specific type of inhibitor, seed type, etc.)

6. Is this material included on the current select agent and toxin list? Yes No

7. What will you be doing with the materials? (n/a if you are the provider of the material)

8. If the materials are being used in conjunction with a current grant or contract, or if they involve materials or processes developed with prior sponsorship, who is the sponsor and which awards are involved?

n/a Sponsor: Award or 5-3 acct #:

9. Are there any conflicts between the terms of this MTA and your current or past funding or other involved MTAs, confidentiality agreements, or intellectual property agreements? If yes, explain. (For example, a private company might require confidentiality but the materials are used on a federal project that cannot promise restricted access to results, or the materials are used with other materials whose MTA terms conflict with this one.)

Page 1 of 2 Updated 2/14/08 cc

of 2 Updated 2/14/08 cc

Material Recipients must answer the questions below.

A. Research that involves any of the following requires approval by the Institutional BioSafety Committee (IBC). Please answer each item below. (IBC application forms, and information on exempt and non-exempt rDNA can be found at http://web.research.colostate.edu/ricro/ibc/ibc.aspx )

1. Does the material itself or the planned use of the material involve infectious agents? Yes No

a) Have you already obtained IBC approval for the agent(s)? Yes No

b) Is an import or export license required? Yes No

c) Have you obtained IBC project approval for the use of the agent? Yes No If yes, please provide IBC project approval number:

2. Does the material itself, or the planned use of the material, involve human blood, body fluids or tissues? Yes No

If yes, please provide the IBC project approval number:

3. Does the material itself, or the planned use of the material, involve recombinant DNA (excluding exempt experiments? Yes No

If yes, please provide the IBC project approval number:

B. If the use of the material will involve animals (research, testing, teaching, breeding, and the like), please provide the Animal Care and Use Committee (ACUC) approval number:

C. If the material will be used for human research, or was collected from humans (cell lines, fluids, tissue samples), please provide the Human Research Committee (HRC) approval number:

http://web.research.colostate.edu/ricro/ibc/ibc.aspx

AUTM | Master UBMTA Agreement Signatories

http://www.autm.net/Technology_Transfer_Resources/8199.htm[2012/07/13 16:33:35]

MEMBER CONNECT ABOUT AUTM ABOUT TECH TRANSFER EVENTS SURVEYS & PUBLICATIONS MARKETPLACE

Home

About Tech Transfer

Technology Transfer

Resources

Public Benefits

Bayh-Dole Act

Links

Valuation Resources

White Papers

FAQs

AUTM Career Center

Techno-L

Network with AUTM

AUTM is a Member of

Home About Tech Transfer Tech Transfer Resources

Master UMBTA Agreement Signatories

1. Aarhus, University of, Lard Bolund, Doctor of Medical Science, Chairman, 06/24/98

2. Academisch Medisch Centrum (Academic Medical Center), Amsterdam, Prof. Dr. M.M. Levi, Chair of the Executive

Board and Dean, 06/12/12

3. AgResearch Ltd., Raakura Research Centre, Dr. Wayne Hein, Animal Health Section Manager, 7/28/09

4. Alabama, University of, at Birmingham, Office of Grants and Contracts Administration, Kenneth J. Roozen, PhD,

Executive VP, 04/26/95

5. Alabama, University of, The Board of Trustees of The University of Alabama for and on behalf of its component

insitution, Donald J. Benson, Ph.D., Vice President for Reseach, 02/09/12

6. Alabama, University of, in Huntsville, The Board of Trustees of the University of, Office of Technology

Commercialization, Lawrence R. Greenwood, PhD, Vice President for Research, 02/20/06

7. Alaska, University of, Craig Dorman, Vice President for Research, 12/02/04

8. Albany Medical College, Thomas J. Irwin, Director, Research Administration, 09/28/04

9. Albert Einstein College of Medicine, Yeshiva University, Sidney Goldfischer, M.D., Associate Dean for Scientific

Operations, 11/30/95

10. Alberta, The University of, Sharlene Coss, Contracts Manager, 04/16/96

11. Allegheny-Singer Research Institute, Chet Cornman, Vice President, 4/17/09

12. Arizona, University of, Michael A. Cusanovich, PhD, Vice President for Research and Graduate Studies, 06/05/95

13. Arkansas State University, Dr. Elizabeth E. Hood, Vice Chancellor for Research and Technology Transfer, 06/01/06

14. Arkansas, The Board of Trustees of the University of, Acting on behalf of all Campuses, B. Alan Sugg, President,

03/26/98

15. Auburn University, C. Michael Moriarty, Associate Provost and Vice President for Research, 06/06/98

16. Aurora Health Care, Inc., Randall Lambrecht, Ph.D., Vice President Research and Academic Affairs, 08/24/11

17. AvidBiotics Corp., David Martin, CEO, 08/12/11

18. Ball State University, Thomas E. Spangler, Associate Vice President for Finance and Assistant Treasurer, 06/28/06

19. Basel, University of, Prof. Dr. Peter Meier-Abt, Vice-Rector, 02/09/11

20. Baylor College of Medicine, James W. Patrick, PhD, Vice President and Dean of Research, 10/20/00

21. Baylor Research Institute, Bernard Brigonnet, CEO, 01/04/11

22. Baystate Health, Inc, Hal B. Jenson, MD, MBA, Chief Academic Officer, 02/13/06

23. Beckman Research Institute of the City of Hope, Eric Jurrus, PhD, Director, Office of Technology, 06/05/95

24. Behavioral Sciences Foundation, Frank Ervin, MD, President, 12/12/08

25. Benaroya Research Institute at Virginia Mason, Kelly Moutsos, Grants & Contracts Manager, 02/08/05

26. Bern, University of, Dr. Daniel Odermatt, Director of Administration, 5/31/10

27. Beth Israel Deaconess Medical Center, Mark Chalek, Director, Office of Corporate Research, 07/01/99

28. Birmingham, University of, United Kingdom, Jean Hammersley, Assistant Director of Finance, 03/11/03

29. Blood Center of Wisconsin and Blood Research Institute, Gilbert C. White, II, M.D., Executive VP for Research,

09/22/11

30. Boehringer Ingelheim RCV GmbH & Co KG, Prof. Dr. Eric Haaksma 04/23/12 and Dr. Erik Patzelt, 04/18/12

31. Boise State University, Mary Givens, Director Office of Technology transfer, 01/07/11

32. Boston Baskin Cancer Group, PLC, d/b/a University of Tennessee Cancer Institute, Phil Sydow, CEO, 01/07/11

33. Boston Biomedical Research Institute, Dr. Kathleen G. Morgan, Sr. Scientist & Director, 05/16/95

34. Boston College, Stephen Erickson, Director, Office of Research Administration, 04/20/95

35. Boston Medical Center Corporation, John Cragin, Associate Director, Grants Administration, 07/02/01

36. Boston University, The Trustees of, Ashley J. Stevens, Director, Office of Technology Transfer, 06/17/04

37. Bowling Green State University, Anthony M. Boccanfuso (contact as of 02/25/04: Heinz Bulmann, Ph.D.), Vice Provost

for Research, 12/04/97

38. Boyce Thompson Institute for Plant Research, Inc., Joyce L. Frank, Vice President for Operations, 11/04/98

39. Brandeis University, Joel M. Cohen, Assistant Provost for Research, 12/04/97

40. Brigham and Women's Hospital, Shelby Calvert Morss, Vice President, 05/23/95

41. British Columbia Cancer Agency Branch, Sarah Jane Lee, Director, Technology Development Office, 9/16/08

42. British Columbia, University of, Richard D. Spratley, Director, Research Services, 11/03/98

43. Brown University, Alice A. Tangredi-Hannon, Director, Office of Research Administration, 08/29/95

44. Buffalo, The Research Foundation on behalf of University of, Charles Kaars, Assistant Vice President, 02/24/03

AUTMGTP

Licensing

eGroups

MemberBlogs

http://community.autm.net/AUTM/AUTM/Home/Default.aspxhttp://community.autm.net/AUTM/AUTM/Home/Default.aspxhttp://www.autm.net/AM/Template.cfm?Section=Abouthttp://www.autm.net/AM/Template.cfm?Section=Abouthttp://www.autm.net/AM/Template.cfm?Section=Tech_Transferhttp://www.autm.net/AM/Template.cfm?Section=Tech_Transferhttp://www.autm.net/AM/Template.cfm?Section=Events1http://www.autm.net/AM/Template.cfm?Section=Events1http://www.autm.net/AM/Template.cfm?Section=Surveyshttp://www.autm.net/AM/Template.cfm?Section=Surveyshttps://www.autm.net/source/Orders/index.cfm?section=Marketplace&task=0&activesection=Ordershttps://www.autm.net/source/Orders/index.cfm?section=Marketplace&task=0&activesection=Ordershttp://www.autmfoundation.org/http://www.facebook.com/pages/Deerfield-IL/The-Association-of-University-Technology-Managers-AUTM/89207340918http://www.facebook.com/pages/Deerfield-IL/The-Association-of-University-Technology-Managers-AUTM/89207340918http://twitter.com/AUTM_Networkhttp://twitter.com/AUTM_Networkhttp://www.linkedin.com/groups?gid=66625&trk=anetsrch_name&goback=.gdr_1250611247485_1http://www.linkedin.com/groups?gid=66625&trk=anetsrch_name&goback=.gdr_1250611247485_1http://www.attp.info/http://www.autm.net/AM/template.cfm?section=homehttp://www.autm.net/AM/Template.cfm?Section=Tech_Transfer&Template=/CM/HTMLDisplay.cfm&ContentID=2979http://www.autm.net/AM/Template.cfm?Section=Technology_Transfer_Resources1&Template=/CM/HTMLDisplay.cfm&ContentID=7886http://www.autm.net/AM/Template.cfm?Section=Technology_Transfer_Resources1&Template=/CM/HTMLDisplay.cfm&ContentID=7886http://www.autm.net/AM/Template.cfm?Section=Public_Benefits&Template=/CM/HTMLDisplay.cfm&ContentID=7863http://www.autm.net/AM/Template.cfm?Section=Bayh_Dole_Act&Template=/CM/HTMLDisplay.cfm&ContentID=7698http://www.autm.net/AM/Template.cfm?Section=Links&Template=/CM/HTMLDisplay.cfm&ContentID=2341http://www.autm.net/AM/Template.cfm?Section=Valuation_Resources_Valuate&Template=/CM/ContentDisplay.cfm&ContentID=1381http://www.autm.net/AM/Template.cfm?Section=White_Papers&Template=/CM/HTMLDisplay.cfm&ContentID=3754http://www.autm.net/AM/Template.cfm?Section=FAQs&Template=/CM/HTMLDisplay.cfm&ContentID=2186http://www.jobtarget.com/home/index.cfm?site_id=3719http://www.autm.net/AM/Template.cfm?Section=Techno_L&Template=/CM/HTMLDisplay.cfm&ContentID=6690http://www.autm.net/AM/http://www.autm.net/AM/Template.cfm?Section=Tech_Transferhttp://www.autm.net/AM/template.cfm?section=homehttp://gtp.autm.net/http://gtp.autm.net/http://gtp.autm.net/http://gtp.autm.net/http://www.autm.net/source/NinePoints/ninepoints_endorsement.cfmhttp://www.autm.net/source/NinePoints/ninepoints_endorsement.cfmhttp://www.autm.net/source/NinePoints/ninepoints_endorsement.cfmhttp://community.autm.net/AUTM/AUTM/Discussions/AllDiscussions/Default.aspxhttp://community.autm.net/AUTM/AUTM/Discussions/AllDiscussions/Default.aspxhttp://community.autm.net/AUTM/AUTM/Discussions/AllDiscussions/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspxhttp://community.autm.net/AUTM/AUTM/Blogs/ViewBlogs/Default.aspx



45. California, The Regents of the University of, Office of Technology Transfer, Terence A. Feuerborn, Executive Director,

06/30/95

46. California, University of, at Santa Cruz, Office of Sponsored Programs, William Clark, Director, 02/02/00

47. California Institute of Technology, Lawrence Gilbert, Director of Technology Transfer, 01/30/96

48. California Pacific Medical Center, David R. Fielder, Vice President, Research, 02/12/98

49. Cambridge University, Martin Reavley, Director, 09/21/10

50. Cardiff University, Geraint Jones, Director, Research and Commercial Division, 03/28/06

51. Carilion Medical Center, Daniel Harrington, MD, Vice President, Academic Affairs, 6/19/09

52. Carnegie Institution of Washington, John J. Lively, Director of Administration and Finance, 03/23/04

53. Carnegie Mellon University, Susan L. Burkett, Associate Provost for Research and Academic Administration, 08/20/03

54. Case Western Reserve University, Richard A. Zdanis, Provost & University Vice President, 07/29/98

55. Cedars-Sinai Medical Center, Shlomo Melmed, Daniel M. Oshiro, Senior Vice President for Academic Affairs,

56. Central Florida, University of, John Miner, Licensing Associate, 7/27/09

57. Centre for Addiction & Mental Health, Dr. Shitij Kapur, Vice President Research, 07/19/04

58. Centre Hospitalier Universitaire De Quebec,Rene Rouleau, Director General, CHUQ, 11/3/08, Jean-Claude Forest,

Director, CRCHUQ, 10/28/08

59. Centre National de la Recherche Scientifique (CNRS), Philippe Pieri, Regional Delegate of the CNRS-Alsace

Delegation, 01/06/09

60. Chicago, The University of, Mary Ellen Sheridan, Assistant Vice President for Research, 05/25/95

61. Children's Hospital & Research Center at Oakland, Antonie H. Paap, President & CEO, 08/16/04

62. Children's Hospital Los Angeles, Nick Goodman, Director, Corporate Relations and Technology Transfer, 04/02/03

63. Children's Hospital of Philadelphia, Robert G. Uris, Vice President, Research, 08/04/98

64. Children's Hospital, Boston, Intellectual Property Office, Donald P. Lombardi, Director, 02/17/00

65. Children's Hospital, Boston, Brenda Manning, Senior Licensing Manager, 05/05/06

66. Chinese University of Hong Kong, The, Mrs. Alice Ngan Yip, Director, Research and Technology Administration Office,

09/06/02

67. Cincinnati Children's Hospital Medical Center, David N. Glass, M.D., Associate Director, CCRF, 03/03/08

68. Cincinnati, University of, Norman M. Pollack, PhD, Director & Intellectual Property and University Pa, 04/19/95

69. City of Hope National Medical Center, Office of Technology Transfer, Eric Jurrus, PhD, Director, 05/30/95

70. Clark University, Richard P. Traina, PhD, President, 08/29/95

71. Clemson University, Y.T. Shah, Chief Research Officer and Senior Vice Provost, 10/12/98

72. Cliniques Universitaires St. LUV (UCL), J. Melin, Medical Director, General Coordinator, 09/17/10

73. CNRS, Neurobiologie Cellulaire et Moleculaire, Dr. Gerard Baux, Director of Laboratory Neurobiologie Cellulaire et

Moleculaire, 01/27/03

74. Cold Spring Harbor Laboratory, Office of Technology Transfer, John Maroney, Director, 03/12/01

75. College of the Holy Cross, Rev. John E. Brooks, President Emeritus, 08/25/95

76. College of William and Mary, Jason P. McDevitt, Director, Technology Transfer, 9/25/09

77. Colorado, University of, System Technology Transfer, Ken Porter, Ph.D., Director of Licensing, and David N. Allen,

Ph.D., Associate Vice President for Technology Transfer, 12/05/05

78. Colorado Seminary (dba: The University of Denver), Margaret Henry, Controller, 02/09/12

79. Colorado State University System, acting by and through Colorado State University, Sponsored Programs, Anthony

Frank, Ph.D., Vice President Research and Information Technology, 08/20/04

80. Concordia University, Dr. Carole Brabant, Acting Director, Office of Research, 11/17/09

81. Connecticut, University of, Health Center, Leonard P. Paplauskas, Assistance Vice President for Research, 05/09/95

82. Connecticut, University of, Thomas G. Giolas, Vice Provost for Research and Graduate Education, 08/05/97

83. Cornell University, Norman R. Scott, VP for Research and Advanced Studies, 10/07/95

84. Creighton University, Kathleen Taggart, Associate Vice President for Research and Compliance, 12/17/10

85. CSIR Biosciences, Dr. Rchikwamba, 08/11/11

86. CSIRO Plant Industry, Richard Steele, Contracts Officer, 04/06/00

87. Dana-Farber Cancer Institute, Office of Technology Transfer, Ruth Emyanitoff, PhD, Director, 05/02/01

88. Delaware, University of, Costel D. Denson, Vice Provost for Research, 04/21/95

89. Department of Molecular Biology, The Institute of Basic Medicine, Chinese PLA General Hospital, Weidong Han,

Associated Professor, 08/08/06

90. Doheny Eye Institute, Ronald E. Smith, M.D., Vice President, 07/26/96

91. East Carolina University, Martha J. S. Van Scott, Director, Office of Technology Transfer, 03/24/04

92. Eastern Virginia Medical School, Robert F. Williams, Ph.D., M.B.A., Director, Office of Technology Transfer, 07/29/03

93. Emory University, Nancy L. Wilkinson, M.P.H., Assistant VP for Research, 10/03/96

94. Ernest Gallo Clinic and Research Center, William R. Sawyers, Chief Administrative Officer, 5/15/09

95. Florida State University, Kirby W. Kemper, Vice President for Research, 9/8/09

96. Florida, University of, Karen A. Holbrook, Vice President and Dean, 08/04/95

97. Forsyth Institute, Richard L. Pharo, Sc.D., Executive Vice President, 08/11/06

98. Fox Chase Cancer Center, Frances Galvin, Assistant Director, Business Development, 05/17/01

99. Fred Hutchinson Cancer Research Center, Technology Transfer, Catherine J. Hennings, Director, 10/19/95



100. Fukuoka University Faculty of Medicine, Mesahide Kuroki, M.D., Ph.D.,Dean, 12/02/10

101. Fundacion Progreso Y Salud, Office of Technology Transfer, Rafael Camacho Fumanal, Director OTT-APHS,

08/11/2006

102. General Hospital of Jinan Military Area, Thoracic Surgery, Lu Zhaotong, Professor and Director, 01/26/02

103. Geneva, University of, Jean-Luc Veuthey, Vice-Rector, 11/02/11

104. GenoCell LLC, Rick Roth, Chief Operating Officer, 07/21/05

105. George Washington University, The, Astra Bain-Dowell, Assistant Vice President for Health Research, Compliance and

Technology Transfer, 09/28/01

106. George Washington University, The, Astra Bain-Dowell, Asst. VP for Health Research, Compliance & Technology

Transfer, 09/28/01

107. Georgetown University, Carol L. Tracy (Updated contact as of 8/5/02: Martin A. Miller, Vice President for Technology

Transfer), Esq., Director of Technology Transfer, 10/04/95

108. Georgia State University, Robin Morris, PhD, Vice President of Research, 9/29/07

109. Georgia, University of, Joe L. Key, Vice President for Research, 02/12/97

110. Georgia, University of, Research Foundation, Inc., Joe L. Key, Executive Vice President, 02/12/97

111. Georgia Tech Research Corporation, Jilda D. Garton, Associate Vice Provost for Research, 09/03/99

112. Girona, University of, Cardiovascular Genetics Center, Guillermo Lavier Perez, Ph.D., 07/10/09. Institutionwithraw acceptance as of 11/14/11

113. Girona, University of, Cardiovascular Genetics Center, 11/14/11

114. Granada, University of, Jesus Chamorro, Deputy-Chancellor, 06/15/12

115. Guangzhou Institute of Energy Conversion, Chinese Academy of Sciences, Yuan Zhen-Hong, Chief Scientist, Dean of

Lab of Biomass Energy Bioconversion, 02/06/07

116. Guelph, University of, Dept. of Environmental Biology, J. Christopher Hall, Ph.D., Professor, 07/15/03

117. Gundersen Lutheran Medical Foundation, William Agger, MD, Director of Research, 11/11/09

118. H. Lee Moffitt Cancer Center and Research Institute, James Mul, Ph.D., ACD, Translational Research/Tech

Development, 09/26/03

119. Harbin Medical University, Department of Pharmacology, Prof. Guoften Qiao, Vice Director, 11/12/10

120. Harvard College, President and Fellows of, Awards Management and Resource Information, Patricia Tucker, Director,

03/07/95

121. Hawaii, University of, Office of Technology Transfer and Economic Develop, Richard F. Cox, Jr. (Original Signatory

was Glenn K. Nakamura), Director, 06/26/98

122. Hebrew University of Jerusalem, Dr. Eran Vardi, Director, Authority for Research and Development, 04/06/10

123. Henry Ford Health System, Nancy J. Hay, MHSA, Director of Research, 01/19/12

124. Het Antoni van Leeuwenhoek Ziekenhuis, Professor A. J. M Berns, Director of Research, 10/14/09

125. Hokkaido University, Grad. Sch. Pharm. Sci., Hideyoshi Yokosawa, Ph.D., Dean, 06/25/06

126. Hong Kong University of Science and Technology, Technology Transfer Center, Roland T. Chin, Vice-President for

Research and Development, 11/12/03

127. Hospital for Sick Children, The, Contracts Office, Anitra Sisavang, Coordinator, 11/11/05

128. House Ear Institute, David J. Lim, MD, Executive Vice President, Research, 09/09/05

129. Houston, University of, Elizabeth Anderson-Fletcher, Associate Vice Chancellor/Vice President for Research and


130. Howard Hughes Medical Institute, Jack Dixon, Ph.D., Vice President and Chief Scientific Officer, 05/09/07

131. Humboldt University, Institute of Biology, Thomas J. Buckhout, Professor, Institute Director, 09/09/99

132. Iceland, University of, Agust H. Ingporsson, Director, Research Liaison Office, 02/03/11

133. Idaho, University of, Charles R. Hatch, Vice President for Research and Graduate Studies, 03/21/01

134. Illinois, Board of Trustees of the University of, Craig S. Bazzani, Comptroller, 03/11/98

135. Illinois at Urbana-Champaign, University of, Research and Technology Management Office, Melvin J. DeGeeter, PhD,

Director, 10/10/95

136. Illinois University at Carbondale, SIUC, John S. Jackson IIII, Vice Chancellor for Academic Affairs and Provost for Jo

Ann Argersinger, Chancellor, 01/22/99

137. Immune Disease Institute, Inc., Ryan M. Dietz, Director, Office of Technology Development, 8/18/10

138. Imperial College of Science, Technology and Medicine, Mirabell Nsofor, Contracts Officer-MTAs, 12/14/11

139. Indiana University, Technology Transfer Office, Dr. Melvin J. DeGeeter, Director, 07/05/95

140. Institut fur Molekulare (IMBA), Dr. Josef Penninger, Director, 06/07/04

141. Institut fur Pharmazeutische Biologie der Rheinischen, Friedrich-Wilhelms-Universitat Bonn, Dr. E. Leistner, Professor,

Geschaftsfuhrender Direktor, 01/09/97

142. Institut fur Vegetative Physiologie, Prof. Dr. med. G. Pfitzer, Director, 3/8/10

143. Institut National de la Recherche Scientifique (INRS), Alain Fournier, PhD., Interim Director, INRS-Institut Armand-

Frappier, 08/09/06

144. Institut Pasteur Korea, Dr. Olf Nehrbass, CEO, 1/20/10

145. Institute for Animal Health, Richard Shaw, Director of Operations, 06/01/12

146. Institute for Biological Energy Alternatives, Inc., J. Craig Venter, Ph.D., President, 09/10/03

147. Institute for Brain Research, Dr. Hans Lassmann, Professor and Director, 05/22/02

148. Institute for Genomic Research, William C. Nierman, PhD, Vice President for Research, 05/21/99

149. Institute for Hygiene and Infectious Diseases in Animals, Justus Liebig University of Giessen, Georg Baljer, Professor



Dr. habil., Head of Institute, 09/20/06

150. Institute for Systems Biology, Leroy E. Hood, MD, PhD, President, Director and Professor, 05/02/01

151. Institute of Biochemistry and Cell Biology (IBCB), Fudi Ni, Director of Academic Administration Department, IBCB,

07/07/05

152. Institute of Botany, Chinese Academy of Sciences, Kang Chong, Professor, 8/31/2009

153. Institute of Chemical Technology, G.D. Yadou, Professor, Vice Chancellor, ICT, 02/24/12

154. Institute of Paper Science and Technology, Gary A. Baum, Vice-President of Research and Academic Affairs, 04/22/99

155. Institute of Plant Biology, China, Wu Ping, Executive Deputy Dean of Life Science College, 01/27/00

156. Institute of Science and Technology Austria (IST), Thomas A. Henzinger, President, 02/11

157. Integrated Biobank of Luxembourg (IBBL), Dr. Jean-Claude Schmit, President of the Governing Board, 4/27/10

158. International University Bremen GmbH, Dr. Alexander Ziegler-Jons, Vice President University Development, 11/29/06

159. Iowa State University, Richard E. Hasbrook (contact as of 2/27/03 Thane Peterson), Contracts and Grants Officer,

08/18/99

160. Iowa State University Research Foundation, Inc., Original signatory: Alan S. Paau (contact as of 2/12/03: Ken

Kirkland), Executive Director, 01/16/96

161. Iowa, University of, Twila Fisher Reighley, Vice President for Research, 12/16/05

162. IUT de Quimper, Adrien Binet, Professor, 06/05/98

163. J. Craig Venter Institute, Inc., (Updated 12/13/04 - Formerly listed as Center for the Advancement of Genomics, Inc.),

9704 Medical Center Drive, Rockville, MD 20850

164. J. Craig Venter/Marvin Frazier (Updated 12/13/04), Ph.D., President/Vice President, Research (Updated 12/13/04),

09/10/03

165. J. Craig Venter Science Foundation Joing Technology Center, Inc., J. Craig Venter, Ph.D., President, 09/10/03

166. J. David Gladstone Institutes, Joan Bruland, Intellectual Property Counsel, 07/08/02

167. Jackson Laboratory, The, David Einhorn, Esq., House Counsel, 01/10/96

168. Johns Hopkins University, Theodore O. Poehler, PhD, Vice Provost for Research, 04/29/98

169. Johns Hopkins University School of Medicine, David A. Blake, PhD, Executive Vice Dean, 05/31/95

170. Joslin Diabetes Center, Carl S. Finn, General Counsel, 08/04/03

171. Juntendo University School of Medicine, Yasuhiko Tomino, Dean, 04/06/10

172. Kansas, University of, Steven F. Warren, PhD, Vice Provost for Research and Graduate Studies, 11/14/08

173. Kansas State University, Paul R. Lowe, Assistant Vice Provost for Research, 03/22/99

174. Kansas Center For Research, Inc., University of, Barbara Armbrister, Director, 07/02/07

175. Kansas Medical Center, University of, Ted Knous, Ph.D., Vice Chancellor for Research Administration, 08/23/05

176. Katholieke Universiteit Leuven, Research & Development, Oliver Lescroart, IPR-Officer, 08/17/06

177. Keio University, Institute for Advanced Biosciences, Masaru Tomita, Ph.D., General Director, 10/04/06

178. Kent State University, Research and Graduate Studies, Eugene P. Wenninger, Vice Provost and Dean, 05/10/95

179. Kentucky Space LLC, Kris Kimel, President, 04/14/11

180. Kentucky, University of, Donald G. Keach, Director, Intellectual Property Development, 08/21/01

181. Lawson Health Research Institute, Sandra Mochodo, Manager, Grants and Contracts, 01/31/06

182. La Jolla Institute for Allergy and Immunology, Charles A. Carpowich, Jr., Chief Operating Officer, Amy M. Klepsch,

Manager, Intellectual Property, 11/16/01

183. Lausanne, University of, Prof. Patrick Francioli, Dean of the Biology and Medicine Faculty, 05/9/10

184. Lehigh University, Office of Technology Transfer, Entrepreneurial Research and Education, Glenn J. Doell, 09/29/06

185. Leland Stanford Junior University, Board of Trustees of, Stefani Shek, Industrial Contacts Associate, 5/19/09

186. Loma Linda Veterans Association for Research and Education, Gayle Rundberg, Executive Director, 05/30/03

187. Los Angles Biomedical Research Institute at Harbor-UCLA Medical Center, L. Jean Remmer, Assistant Vice President,

Research Administration, 6/24/08

188. Louisiana State University, Board of Supervisors of acting on behalf of the University of New Orleans, Agricultural and

Mechanical College, Mary Louise Trammell, PhD, Associate Vice Chancellor for Research and Director of Technology

Transfer, 10/15/97

189. Louisiana State University and A&M College, The Board of Supervisors of, H. Douglas Braymer, VP for Academic

Affairs and Technology Transfer, 10/13/95

190. Louisiana State University Health Sciences Center - Shreveport, Robert A. Barish, M.D., M. B. A., Chancellor,

04/28/2010

191. Louisville, University of, Nancy C. Martin, Vice President for Research, 03/06/97

192. Lovelace Respiratory Research Institute, Chris Merriam-Leith, Director of Business Affairs, 07/21/11

193. Loyola University Chicago, David S. Crumrine, Associate Directory, Research Services, 03/29/00

194. Lund, University of, Department of Cell and Molecular Biology, Charlotte Erlanson-Albertsson, Ph.D., Professor,

10/06/03

195. Maine Medical Center Research Institute, James W. Donovan, Associate Vice President for Medical Affairs, 11/14/03

196. Manchester, University of, Research Office, Karen Shaw, Head of the Research Office, 09/21/10

197. Manitoba, University of, T.G. Falconer, Vice President (Administration), 10/25/95

198. Mario Negri Institute, Prof. Silvio Garattini, Director, 9/22/09

199. Marshfield Clinic Research Foundation, A Division of Marshfield Clinic, Steve Wesbrook, Ph.D., Deputy Director,

02/25/09



200. Maryland, University of, at Baltimore, Office of Sponsored Programs Administration, Marjorie Forster, Director, 06/27/95

201. Maryland, University of, at Baltimore County, Dr. Michael Breton, Assistant Vice Provost for Research, 09/11/98

202. Maryland, University of, at College Park, Antoinette Lawson, Associate Director, 10/12/11

203. Massachusetts Eye and Ear Infirmary, Office of Research Administration, Elayn G. Byron, CRA, Director, 04/26/04

204. Massachusetts General Hospital, Licensing and Industry Sponsored Research, Marvin C. Guthrie, JD, VP, Patents,

04/24/95

205. Massachusetts Institute of Technology, Technology Licensing Office, Lita L. Nelsen, Director, 04/26/95

206. Massachusetts Medical School, University of, Office of Technology Management, James P. McNamara, Ph.D.,

Executive Director, OTM, 10/05/05

207. Massachusetts Medical School, University of, Peter E. Newburger, MD, Professor of Pediatrics and Cancer Biology,

04/05/06

208. Massachusetts, University of, Commercial Ventures & Intellectual Property, William S. Rosenberg, Ph.D., Executive

Director, CVIP, 10/07/05

209. Max-Delbruck-Centrum Fur Molekulare Medizin (MDC), Christine Rieffel-Braune, Head of Legal Department &


210. Max Planck Florida Corporation/ Max Planck Florida Institute, Dr. Ivan C. Baines, Chief Operating Officer, 02/16/11

211. Max Planck Institute of Molecular Cell Biology and Genetics, Anthony A. Hyman, Director, 05/12/05

212. Max Planck Institute for Developmental Biology, Dr. Detlef Weigel, Executive Director, 9/10/09

213. Mayo Clinic Arizona, (current contact as of 5/23/12, Virginia M. Bruce, Director, Legal Contract Administration), Mary J.

Hoffman, Secretary & Assistant Treasurer, 03/26/97

214. Mayo Clinic Jacksonville (current contact as of 5/23/12, Virginia M. Bruce, Director, Legal Contract Administration),

Jeffrey Scheffel, Chair Division of Research Services, 09/22/06

215. Mayo Clinic, (c(current contact as of 5/23/12, Virginia M. Bruce, Director, Legal Contract Administration), Bonnie

Edwards, Assistant Treasurer, 11/24/00

216. Mayo Foundation for Medical Education and Research, (current contact as of 5/23/12, Virginia M. Bruce, Director,

Legal Contract Administration), Rick F. Colvin, Assistant Treasurer, 06/30/97

217. McGill University, McGill University Health Centre (MUHC), Office of Technology Transfer, Alex Navarre, Director,

Office of Technology Transfer, 10/12/03

218. Medical Center of Central Massachusetts, Peter H. Levine, MD, President and CEO, 08/30/95

219. Medical College of Georgia, School of Graduate Studies, Matthew J. Kluger, PhD. MBA, Vice President for Research

and Dean, 07/26/99

220. Medical College of Pennsylvania Hahnemann University, Kathleen A. Denis, PhD, Vice President, Technology


221. Medical University of South Carolina, Dillard C. Marshall, Director, Research Administration, 11/01/95

222. Medicine and Dentistry, New Jersey, University of, Frederick J. Hammond, Jr., Senior VP for Administration and

Finance, 09/05/95

223. Medizin Universitat Innsbruck, Innsbruck, Austria, Dr. Gunther Speru, Vice-Rector Research, Dr. Sonja Schmidl, Head

of the Leagal Department, 03/05/11

224. Memorial Sloan-Kettering Cancer Center and Memorial Sloan-Kettering Institute for Cancer Research, Andrew D.

Maslow, Director, Office of Industrial Affairs, 11/18/05

225. Memphis, University of, Andrew Meyers, Ph.D., Vice Provost for Research, 8/16/10

226. Miami, University of, Robert W. Rubin, Vice Provost for Research, 03/19/96

227. Michigan State University, Norman M. Pollack, PhD, Assistant Vice President for Intellectual Property, 11/13/01

228. Michigan Technological University, (current contact as of 11/21/01: Dr. David D. Reed, VP for Research), Dr. Sung M.

Lee, Vice Provost for Research, 05/02/96

229. Michigan, University of, Division of Research Development & Administration, Marvin G. Parnes, Associate Vice

President for Research, 10/13/00

230. Minnesota, Univ of, Office of Research & Technology Transfer, Orig. Signatory: A.R. Potami, Associate Vice President,

Current Contact: Tony Strauss, Acting Assistant Vice President, 07/20/95

231. Mississippi State University, Richard Swann, Director, Sponsored Programs Administration, 5/21/10

232. Mississippi, University of, Ronald F. Borne, Interim Vice Chancellor for Research, 05/18/00

233. Missouri, University of, at Columbia, Office of Sponsored Prog. Administration, Richard J. Otto, Director, 06/13/95

234. Missouri, University of, at Kansas City, Edgar J. Ellyson, PhD, Director, Grants & Contracts, 06/08/95

235. Missouri, University of, at Rolla, Dr. Walter J. Gajda, Jr., Vice Chancellor for Academic Affairs, 06/30/95

236. Missouri, University of, at St. Louis, Dr. Douglas Wartzok, Associate Vice Chancellor for Research, and Graduate

Dean, 05/17/95

237. Monash University, Rocco Iannello, Business Development Manager, 10/14/10

238. Montana State University, Rebecca W. Mahurin, Ph.D, Director, Technology Transfer, 1/14/08

239. Mount Sinai Hospital, Samuel Lunenfeld Research Institute, Patents and Licensing, Terry Donaghue, Manager,

05/02/95

240. Mount Sinai School of Medicine, Office of Technology & Business Development, Kathleen P. Mullinix, Ph.D., 12/07/10

241. Institute for Cellular and Molecular Biology, Robert M. Krug, Ph.D., Professor, 09/06/06

242. National Chung Hsing University, Ru-Jong Jeng, 07/17/06

243. National Medial Center, Dr. Balazs Sarkadi, Scientific Vice Director, 10/25/2006

244. National Institute of Dental and Craniofacial Research (NIDCR), David W. Bradley, Ph.D., Technology Development

Coordinator, 10/31/11



245. National Institutes of Health, LBC, Dr. Albert Fornace, Acting Chief, 03/26/97

246. National University of Ireland, Galway, Daniel O'Mahony, Director, Technology Transfer, 02/16/06

247. National University of Ireland Maynooth, Prof. Ray O'Neill, Vice president for Research, 05/31/12

248. National University of Singapore, Irene Cheong, Director, Industry Liaison Office, 10/27/10

249. Nebraska-Lincoln, University of, David Conrad, Associate Vice Chancellor for Technology Development, 10/12/08

250. Nebraska, University of, Medical Center, William O. Berndt, PhD, Vice Chancellor for Academic Affairs, 03/08/00

251. Nanyang Technological University, Yehuda Yarmut, Director, Enterprise & Technology Development, Nanyang

Innovation & Enterprise Office, 01/18/11

252. Nevada Cancer Institute, Meredith Mullins, Associate Center Director, Sr. Vice President, Research Operations and

Research Administration, 01/25/10

253. Nevada, University of at Las Vegas, Dr. Paul W. Ferguson, Vice President for Research and Graduate Studies,

03/27/06

254. Nevada, University of, Reno, Technology Transfer Office, Ryan A. Heck, J.D., Ph.D., Patent Counsel and Director,

02/25/10 and Daniel Klaich, Chancellor, Board of Regents of the Nevada System of Higher Education on behalf of the

University of Nevada, Reno, 11/08/11

255. Newcastle University, Dr. Amanda Gregory, Grants and Contracts Manager, 01/26/10

256. New England Deaconess Hospital, David Kiszkiss, VP, Research, 05/01/95

257. New England Medical Center Hospitals, Inc., Technology Administration, Fred Reinhart, Director, 09/11/95

258. New Hampshire, University of, Kathryn B. Cataneo, Executive Director, 03/31/99

259. New Jersey Institute of Technology, Dr. Raquel Perez-Castillejos, Assistant Professor, 12/9/2008

260. New Jersey Institute of Technology, Donald H. Sebastian, Sr. VP for Research and Development, 12/8/08

261. New Mexico, University of, Nasir Ahmed, PhD, Associate Provost for Research, 06/12/00

262. New York Medical College, Catharine Crea, Associate Dean for research Administration, 01/04/11

263. NIMH, Robert M. Cohen, PhD, MD, Lead Clinical Investigator, 08/22/97

264. North Carolina at Chapel Hill, University of, Technology Development, Francis J. Meyer, Associate Vice Chancellor &

Director, 10/04/95

265. North Carolina Central University, James H. Ammons, Chancellor, 06/08/04

266. North Carolina State University, Dr. David Winwood, Assistant Vice Chancellor for Technology Transfer, 03/16/01

267. NorthShore University HealthSystem, Stephen Wachtel, Ph.D., Director, Research Development, 01/07/09

268. North Texas Health Science Center, University of, Research and Biotechnology, Robert W. Gracy, Ph.D., Associate

VP, 04/26/04

269. Northeastern Ohio Universities, College of Medicine, Robert S. Blacklow, MD, President and Dean, 07/16/95

270. Northeastern Ohio Universities College of Medicine, Robert S. Blacklow, MD, President and Dean, 07/16/95

271. Northeastern University, William E. Kneeland, Jr., Controller, 05/19/05

272. Northern California Institute for Research and Education, Jack Nagan, Chief Executive Officer, 09/10/99

273. Northern Illinois University, Jerrold H. Zar, Associate Provost for Research, 04/03/95

274. Northern Kentucky University, William F. Thompson, Director, Research, Grants and Contracts, 01/11/12

275. Northwestern University, Technology Transfer Program, Indrani Mukharji, PhD, Director, 04/28/99

276. Notre Dame, University of, James L. Merz, Vice President for Graduate Studies & Research, 05/14/97

277. Nova Southeastern University, Gary S. Margules, Sc.D., Vice President, Office of Research and Technology Transfer,

03/31/10

278. Oakwood Healthcare, Inc., Gregory J. Bock, Designated Institutional Official, 12/02/11

279. Odense University Hospital, Department of Hematopathology, Michael B. Moller, Associate Professor, Director,

02/27/10

280. Ohio, Medical College of, R. Douglas Wilkerson, PhD, Associate VP for Research, 07/12/95

281. Ohio State University, Technology Licensing, Robin L. Rasor (Updated as of 10/15/02 Lisa Rooney, Acting Director),

Director, 12/20/99

282. Ohio University, Lisa Rooney, Director, Technology Transfer, October 15, 2008

283. Oklahoma, The Board of Regents of the University of, W. Arthur Porter, University Vice President for Technology


284. Oklahoma Medical Research Foundation, J. Donald Capra, MD, President, 12/22/99

285. Oklahoma State University, Thomas C. Collins, PhD, Vice President for Research, 01/25/96

286. Old Dominion University, Dr. Mohammad Karim, Vice President Research, 03/21/05

287. Ontario Cancer Institute, Technology Transfer, Bob McArthur, Director, 09/29/98

288. Oregon, University of, Technology Transfer, Don Gerhart, Director, 04/02/98

289. Oregon Health Sciences University, Technology Management, Sandra L. Shotwell, PhD, Director, 04/24/95

290. Oregon State University, Dr. George H. Keller, Vice Provost for Research and International Programs, 07/03/95

291. Ottawa, University of, D. Joe Irvine, Director, Technology Transfer & Business Enterprise, 08/22/06

292. Pennsylvania State University, Ronald J. Huss, Director, Intellectual Property Office, 12/12/05

293. Pennsylvania, University of, Center for Technology Transfer, Anthony Merritt, Executive Director, 05/02/95

294. Pioneer Valley Life Sciences Institute, Inc., Paul Friedmann, PhD, Executive Director, 03/28/06

295. Pittsburgh, University of, Allen DiPalma, Director, Office of Research, 7/1/08

296. Polytechnic University, Michael Klidas, Director of Contracts and Grants, 06/22/06

297. Poudre Valley Health System, Stephanie Doughty, Vice President/ Chief Financial Officer, 02/09/12



298. Prairie View A&M University, William Trotty, Vice President for Research and Development, 11/24/00

2

Date post:	26-Jul-2018
Category:	Documents
Upload:	duongkien
View:	248 times
Download:	1 times

Material Transfer Agreement (MTA) · Material Transfer Agreement (MTA) ... The Uniform Biological...

Documents